Cerebrolysin®
1ml, 5ml and 10 ml ampoules / 30ml, 50ml vials
For the modern, safe and effective treatment of disturbed cerebral functions

Composition
Cerebrolysin® is a peptide preparation. The solution, ready for injection or infusion, is free of proteins, lipids and antigenic properties. 1ml of Cerebrolysin® concentrate as active ingredient in aqueous solution.

Route of administration
Solution for intramuscular and intravenous injection or intravenous infusion.

Pharmacodynamics
The efficacy of Cerebrolysin® is proven in numerous animal experiments and clinical trials. Cerebrolysin® is a brain-specific peptidergic nootropic drug able to affect the central nervous system in a multimodal way. This multimodal action of Cerebrolysin® expresses itself as: 1) regulation and improvement of the neuronal metabolism which prevents lactacidoses in hypoxic or ischaemic episodes, 2) modulation of the synaptic plasticity which corresponds to an improvement of behaviour and learning capacity, and 3) a completely unique neurotrophic effect, including neuronal differentiation, guaranteeing full neuronal function and protection against different types of ischaemic and neurotoxin lesions.

In Controlled clinical trials Cerebrolysin® treatment leads to an improvement in the cognitive performance and mood of patients suffering from Alzheimer’s disease. Therefore, the amount of care needed by these sufferers decreases. In these patients marked improvement is observed in 61.7% of the Cerebrolysin® - treated group (as assessed by the Clinical Global Impressions scale CGI). Another clinical trial in patients with vascular dementia demonstrates enhancement of memory performance in the group receiving Cerebrolysin® treatment. An improvement in the global clinical picture is also noticed in this illness. A further study involving patients from nine different disease entities established the effectiveness of Cerebrolysin® through the use of 11 psychological tests subjected to a variance analysis.

After stroke and craniocerebral trauma treatment wit Cerebrolysin® leads to an accelerated recovery.

Literature on Cerebrolysin® is available upon request.

Pharmacokinetics
Cerebrolysin® passes through the blood-brain barrier. Up to eight hours after iv administration of Cerebrolysin® neurotophic activity can be detected in the human long-lasting effects even after a single iv administrarion.

Toxicological properties
Cerebrolysin® is generally well tolerated and possesses an extremely high margin of safety. In human therapeutic dosages this produces almost no toxic symptoms. The toxicological data are listed below.

Acute toxicity: after a single iv administration of Cerebrolysin® the following LD₅₀ values were observed (14 days observation period): male rats 68ml/kg body weight, female rats 74ml/kg body weight; dogs, male and female >52.2ml/kg body weight. Chronic toxicity (multiple doses over six months) rats received up to 12.5ml/kg body weight daily for 26 weeks. Only moderate changes in the blood count were observed, dogs; the highest administered doses were 9ml/kg body weight daily for 28 days (about 10 times the human therapeutic dosage) and 4.5ml/kg body weight daily for 26 weeks (about five times the human therapeutic dosage): no systemic substance-dependent intolerance reactions were observed.

Reproductive toxicity: Cerebrolysin® was injected iv to the dams at the highest possible volumes: in no case was an alteration of the gestagenic period observed, in rabbits. Neither embryotoxic nor teratogenic effects nor impairments of embryonic or neonatal developments were found; no influence on the progeny (F₁ and F₂ generations) was evident. Influence on the fertility and reproductive performance of the parent animals potential, effect or carcinogenicity in toxicological tests, neither in vitro nor in vivo.

**Indications**
- disturbances of concentration and memory
- degenerative dementias, including Alzheimer’s disease
- vascular demenatias, eg multi-infarct dementia
- mixed forms of dementia (degenerative and vascular contribution)
- sequels of stroke (ischaemic and haemorrhagic)
- posttraumatic or postoperative complaints, eg following cerebral contusion, concussion, or neurosurgical operation.

**Contraindications**
- hypersensitivity to one of the components of the drug
- status epileptics or grand mal conulsions; an increase in the seizure frequency may be seen in these cases
- status epileptics or grand mal conulsions; an increase in the seizure frequency may be seen in these cases
- severe impairments of renal function

**Slide effects**
Cerebrolysin® is generally well tolerated. If injected too fast it may cause a moderate heat sensation. In extremely rare cases a hypersensitivity reaction manifested itself as chills, headaches or as slight increase in body temperature the cause of which is probably the hyperresponiveness of the patient. In no case to date has the undesirable effect persisted or proved threatening to the patient.

**Warning and precautionary measures**
Patients with severe renal impairment must be excluded from a Cerebrolysin® therapy. Animal experimental data did not show any evidence to teratogenic
effects. There is no clinical experience with Cerebrolysin® in women. Therefore, unless the potential benefits outweigh any potential risk. Cerebrolysin® should not be administered during pregnancy and the lactation period.

**Interactions**
The concomitant administration of Cerebrolysin® with antidepressive drugs or MAO inhibitors can lead to cumulative effects. In these cases a dose reduction of the antidepressive drug is advisable.

**Dosage and administration**
Cerebrolysin® is available in 1ml, 5ml and 10ml ampoules and vials of 30ml and 50ml. Up to 5ml per intramuscular administration, for administration over 5ml an intravenous injection or infusion is advised. Cerebrolysin® can also be given diluted in a standard iv solution (e.g. physiological saline solution, flinger’s solution, glucose 5%, dextran 40) infused slowly over approximately 20 to 60 minutes. Once daily application of Cerebrolysin® for a minimum of 10 to 20 days are recommended. This constitutes a course of therapy. In mild cases 1-5ml, in severe cases 10-30ml should be applied. The length of the therapy and the individual doses on the age of the patient as well as on the disease. Usually a treatment period of three to four weeks is recommended. Therapy courses can be repeated several times in accordance with the clinical picture of the patient until no further improvement can be observed. Therapy-free intervals should be maintained between courses. In severe cases it is advisable not to interrupt treatment abruptly but to continue with one injection every other day for a period of four weeks. From the above mentioned clinical trials the following daily dosage guits can be deducted dementias 3-50ml daily, in postapplectic deficits and brain injuries 10-50ml daily.

**Presentation and packs**
- Original packs with 10 ampoules of 1ml
- Original packs with 5 ampoules of 5ml
- Original packs with 5 ampoules of 10ml
- Original packs with 5 vials of 30ml
- Original packs with 5 vials of 50ml

**Storage**
Keep in a safe place out the reach of children. Store at room temperature not over 25°C, away from light.